

## Serosurveillance of SARS CoV 2 among the healthcare workers of a tertiary care teaching institution in Central Kerala during the post lockdown phase

Dr. Aboobacker Mohamed Rafi<sup>1</sup>, Dr. Maglin Monica Lisa Joseph Tomy<sup>1</sup>, Dr. Ronnie Thomas<sup>\*2</sup>, Dr.Chithra Valsan<sup>3</sup>, Mr.U G Unnikrishnan<sup>4</sup>, Dr.Susheela J Innah<sup>1</sup>, Dr. Praveenlal Kuttichira<sup>5</sup>

<sup>1</sup>Transfusion Medicine & Clinical Lab, Jubilee Mission Hospital, Medical College & Research Institute, Thrissur, India.

\*Corresponding author

<sup>2</sup> Department of Community Medicine, Government Medical College, Kottayam, India

<sup>3</sup>Department of Microbiology, Jubilee Mission Hospital, Medical College & Research Institute, Thrissur, India.

<sup>4</sup>Department of Community Medicine, Jubilee Mission Hospital, Medical College & Research Institute, Thrissur, India.

<sup>5</sup>Principal, Jubilee Mission Hospital, Medical College & Research Institute, Thrissur, India.

### Abstract.

**Background** Kerala was the first state to have the confirmed case of COVID-19 in the country and it was first confirmed in Thrissur district on 30 January 2020. Our institute being in the heart of the city had to take adequate measures to mitigate the spread and treat the required patients by keeping its staff safe & Healthy. The hallmark of COVID 19 infection is high infectivity, pre-symptomatic transmission and asymptomatic prevalence which could result in high cumulative numbers of infections, hospitalizations, and deaths. Kerala was the first state to confirm community transmission in July 2020. Health care workers being in the forefront in the war against COVID19 are very prone in acquiring the infection and are possible to be asymptomatic sources for cluster formation. Knowing the development of immunity as shown by the presence of anti COV2 antibodies in the population contributes to the epidemiological understanding of the disease. The intent of the study is to do an antibody testing in our hospital to find the serosurveillance of SARS CoV 2 among the healthcare workers in our hospital.

**Aim:** To estimate the seropositivity of SARS CoV 2 among the healthcare workers at Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, six months after revoking the lockdown

**Methodology:** A cross sectional study among the health care workers of the medical college. Multistage Sampling was done with the hospital block as the first stage and departments as the second stage. In the final stage of sampling the test individuals were selected on a first come first served basis after the antibody test availability was declared open and free for all staff. A consent form and a Google form were given to all staff who volunteered for participating in the study. Each consented participant recruited into the investigation completed a questionnaire which covers details regarding demographics, exposure history, Residence & travel. Blood sample was collected and

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.27.21250502>; this version posted January 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Anti-SARS COV2 IgG antibody testing which targets the Spike Protein (SP1) was done using the VITROS chemiluminescence platform (Orthoclinical diagnostics, USA). Sampling & testing ranged over a time frame from September 5<sup>th</sup> to December 15<sup>th</sup>, 2020

**Results:** Jubilee Mission Medical College has 2785 working staff at the time of study. A total of 420 staff consented and their samples were tested. 37 staff members tested positive for COVID-19 antibody, yielding an overall prevalence of 8.75% (95% CI, 6.23–11.86). 86.5 % (32/37) of them were having a history of COVID-19 Antigen / RT PCR Positivity. We identified a statistically significant linear trend (p value =0.00001), between seropositivity and the degree of severity of COVID 19. Among the various factors which increase the risk of seroconversion, history of undergoing quarantine (p value < 0.001), contact with a confirmed case (p value = 0.002), contact with a caregiver for COVID 19 (p value =0.001) and history of Upper respiratory symptoms (p value =0.001), were found to be significantly associated with positive serology.

**Conclusions:** The overall seropositivity in the current study was found to be 8.75% which is comparable to seroprevalence studies conducted in the United States and Wuhan in China. The pattern of seropositivity across the different category of health workers observed in the present study showed a higher prevalence among nurses. This result is also in agreement with a recent published report from united states. Various measures advised by the national and state health authorities were adequately adhered to. Keeping track of the pattern of development of immunity in the community is part of understanding the illness and forecasting the spread. For the tested HCW, it will boost up morale by ending uncertainty. For the hospital administration it will help in decision making about relative focusing of interventions on patients in general and HCWs. By knowing the immunity status of HCWs, the Institution will be able to contribute authentically to the development of intervention strategies and guidelines from time to time, besides following the available guidelines. Being an educational institution, it is obligatory to train all the elements of care delivery to the future generation of health care workers. Getting experienced from a small but relevant sample was expected to facilitate larger community study envisaged in peripheral areas Jubilee served

## Introduction

The hallmark of SARS-CoV-2 pandemic is high infectivity, pre-symptomatic transmission and asymptomatic prevalence which results in high cumulative numbers of infections, hospitalizations and deaths.<sup>1</sup> In India, Kerala was the first state affected by COVID-19, and the first coronavirus case was confirmed in Thrissur district on 30 January 2020.<sup>2</sup> By early March, the state had the highest number of active cases in India mainly due to a huge number of cases imported from other countries and states. Using the five components of trace, quarantine, test, isolate and treat, by 10 June 2020, Kerala managed to keep the basic reproduction number at 0.454 against the India and world averages from 1.225 and 34.<sup>3</sup>

The state of Kerala has witnessed a long lag phase after the first reported case of COVID 19 on Jan 30<sup>4</sup> till the phase of community spread and has managed to delay the peak of the pandemic by successful implementation of various control measures. In each phase starting from the reporting of the first case in India, our hospital along with other hospitals in the state have taken appropriate control measures to fight against the pandemic<sup>5</sup>. It is important to have knowledge about the effectiveness of the steps taken, in planning the future strategies for disease control. Silent infection is a major concern. It is also important to

know if health care workers act as a source of infection to patients during a pandemic, especially when hospitals serve other patients also. Being a novel virus, little is known about various aspects of the virus; the factors contributing to its spread, the progression of the disease, development of immunity etc. Knowing the development of immunity as shown by the presence of antibodies in the population contributes to the epidemiological understanding of the disease. Studies on seroconversion rates in a population helps to find out the exposure to the virus in that population, be it symptomatic or asymptomatic<sup>6</sup>. WHO continues to review the evidence on antibody responses to SARS-CoV-2 infection. Most of these studies show that people who have recovered from infection have antibodies to the virus. Sero-prevalence among various categories of tested individuals reported from various parts of India ranged from 0.73 to 19.8<sup>7-13</sup>. So far, little is known about it related to Kerala. Seroprevalence studies conducted by the ICMR during the first two phases shows a gradual rise from 0.33 % in May to 0.8% in August 2020.<sup>14</sup> Hence, we planned to undertake an antibody testing among health workers in our hospital.

**Aim:** To estimate the seropositivity of SARS CoV 2 among the healthcare workers at Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, six months after revoking the lockdown

**Objectives:** We intended to find out the seropositivity in health care workers for COVID 19 during the rising graph of pandemic incidence in this part of Kerala, and to compare with reports from elsewhere in the country.

**Methodology:** The Institutional Review Board approval was obtained for this study. The study was conducted among the HCWs at Jubilee Mission Medical College & Research institute, Thrissur, a 1600 bedded teaching hospital with around 3000 staff in the regular pay rolls, daily wagers and workers of service contractors. This study was designed as a cross sectional study. All categories of staff working in the hospital and medical college comprised the study population. A rising graph of incidence was operationally defined as a period up to daily incidence in the state above 10000 and or daily COVID In Patient strength in our hospital as 100 or above.

**Sample Size:** Sample size was calculated by the formula  $n = (Z\alpha)^2 \times p \times q / d^2$ .  $Z\alpha$  is the Z value at an  $\alpha$  error of 0.05. i.e., 1.96 for a 95% confidence interval  $p$ , 23%, is the proportion of subjects with positive SARS COV2 antibodies according to a study done by Percivalle E et al during the peak of epidemic in Italy<sup>6</sup>.  $q$  is 100- $p$ .  $d$  is clinically allowable error which was taken as 20% of prevalence. The minimum sample size required was calculated to be 320

**Sampling Technique:** Multistage Sampling was done with the hospital block as the first stage and departments as the second stage. In the final stage of sampling the test individuals were selected on a first come first served basis after the antibody test availability was declared open and free for all staff. A consent form and a Google form were given to all staff who volunteered for participating in the study. Research staff helped the volunteers to detail the consent form and filling up of the proforma in Google

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.27.21250502>; this version posted January 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

form. Each consented participant recruited into the investigation completed a questionnaire which covers demographic information, exposure history, Residence details (containment zone or not), travel and details of family exposure.

**Sample collection:** After obtaining informed consent 3 ml of blood was collected in EDTA vacutainers, centrifuged and the plasma was separated. The plasma was subjected to antibody testing by Chemiluminescence Immunoassay. The kit used was manufactured by Ortho clinical diagnostics (USA). The kit was used in the Vitros equipment. The blood samples were tested for the presence of Anti SARS COV2 IgG antibody. Testing Time period: The process of Recruitment & Sampling started on 5th September 2020 and ended on 15th December 2020.

**Testing Methodologies:** We used the chemiluminescence technology for antibody testing. These tests can target the Spike-protein S1 antigen, Spike-protein S2 antigen, nucleocapsid antigen, or a combination. The assay which we used in this study was Vitros anti-SARS-COV-2 IgG, which targets the S1 spike protein. As compared to other coronaviruses, S1 protein is more specific and unique to COVID-19. The test kit used in the present study has a sensitivity of more than 90% and specificity of nearly 100%. Lin et al reported the superiority of chemiluminescence-immunoassay over the ELISA method.<sup>15</sup>

The details and results of the tests done were recorded. For those HCWs who became positive in antibody testing, the details were shared with the institutional medical board and further necessary action if found was offered as per Kerala government guidelines and Institutional policy. Antibody positive status among tested samples were calculated and considered as seropositivity. It was calculated overall for all HCWs and separately for different categories of them.

### **Statistical Analysis**

For the summary of demographic characteristics, continuous variables were summarized as mean values and standard deviation while categorical variables were summarized as proportions. The  $\chi^2$  test was used for comparing the epidemiological features between positive and negative cases. Chi square for trend analysis was done for exploring the relationship of the degree of severity with test positivity. All analyses were conducted using SPSS version 25.

### **Observations and Results:**

Jubilee Mission Medical College & Research Institute has 2785 working staff at the time of study. A total of 423 staff (Table 1) consented and their samples were tested. This included 77 Doctors, 104 nursing staff, 85 technicians, 31 administrative /ministerial staff and 126 support staff. During the study period, 37 staff members tested positive for COVID-19 antibody, yielding an overall prevalence of 8.75% (95% CI, 6.23–11.86). 86.5 % (32/37) of them were having a history of COVID-19 Antigen / RT PCR Positivity.

Category	Working	Tested	Positive	Seropositivity
Doctors	486	77	5	6.5
Nurses	978	104	12	11.5
Technicians	154	85	6	7.1
Administrative Ministerial	48	31	0	0.0
Support	1119	126	14	11.11
<b>All</b>	<b>2785</b>	<b>423</b>	<b>37</b>	<b>8.75</b>

**Table1: Test and result status of antibody to SARS-COV2 among Health Care Workers**

The mean age of positive and negative employees was 35.35 and 34.46 years, respectively (Table 2). Employees who were females comprised a greater proportion of study subjects and there was no statistically significant difference in the seroprevalence ( $P = 0.327$ ).

Attribute		SARS CoV 2 Antibody		P value
		Positive (n=37)	Negative (n=386)	
Mean Age		35.35 ± 9.69	34.46 ± 10.59	0.624
Gender	Male	8 (29.3%)	120 (21.6%)	0.327
	Female	29 (70.7%)	266 (78.4%)	

**Table 2: Age & Gender**

The various risks for seroconversion were analyzed. Among the various factors which increase the risk of seroconversion, history of undergoing quarantine ( $p$  value < 0.001), contact with a confirmed case ( $p$  value = 0.002), contact with a caregiver for COVID 19 ( $p$  value =0.001) and history of Upper respiratory symptoms of COVID 19 ( $p$  value =0.001), were found to be significantly associated with positive serology.( Table 3)

SI.No	Attribute	SARS COV 2 Antibody		P value
		Positive (n=37)	Negative (n=386)	
1	History of symptoms suggestive of COVID 19 in the past 3 months	Yes	26	0.001*
		No	11	

2	History of contact with a confirmed case/Quarantined individual	Yes	24	147	<b>0.002*</b>
		No	13	239	
3	History of Travel outside Kerala since COVID outbreak	Yes	1	9	<b>0.997</b>
		No	36	377	
4	History of undergoing Quarantine	Yes	27	85	<b>&lt;0.001*</b>
		No	10	301	
5	History of taking Covid 19 testing (RT-PCR/Antigen)	Yes	30	160	<b>&lt;0.001*</b>
		No	7	226	
6	Adherence to PPE protocols of HICC	Yes	35	370	<b>0.715</b>
		No	2	16	
7	History of contact with a caregiver for Covid 19 patients	Yes	24	142	<b>0.001*</b>
		No	13	244	

**Table 3: Chance of exposure and SARS COV 2 antibody status**

**The degree of severity of symptoms and the antibody response was also analyzed.** We identified a statistically significant linear trend ( $p$  value =0.00001), between seropositivity and the degree of severity of symptoms of COVID 19 (Table 4).

Severity of Symptoms in past 3 months	SARS COV 2 Antibody Status		Odds ratio
	Positive (n=37)	Negative (n=386)	
Asymptomatic	9 (24.3%)	287 (76.1%)	1
Mild Upper Respiratory Symptoms	8 (21.6%)	69 (18.3%)	3.22
Moderate Symptoms	17 (45.9%)	29 (7.7%)	18.62
Severe	3 (8.1%)	1 (0.26%)	95.33

Table 4: Severity of symptoms and SARS COV 2 antibody status

Chi- Square for trend. P value =0.00001

**Discussion:** The initial ‘Kerala model’ of response to the COVID-19 pandemic was to trace contact and quarantine or test, isolate and treat all travelers from foreign countries as well as neighboring states, coupled with lockdown and break the chain measures. This practice had made the state succeed in

preventing community spread in the initial months of the Pandemic. With unlocking according to national policy and easing of restrictions, the community transmission was inevitable. Kerala was the first state in the country to declare community transmission in the Trivandrum district among the coastal region<sup>16</sup>. There is always a high risk of transmission to the healthcare worker (HCW) from pre-symptomatic and asymptomatic patients reporting with non-COVID illness, especially in non-COVID-19 hospitals. Identifying infected HCWs, including asymptomatic ones, is important to reduce nosocomial spread<sup>17</sup>.

Initially a stratified random sampling was decided as the sampling technique. Risk groups were considered as the strata of the study. Hospital employees were stratified into four risk groups namely High risk, Moderate risk, Low risk and Very low risk based on the likelihood of exposure to a suspected COVID 19 patient, frequency and duration of exposure and the nature of interventions being performed. WINPEPI was used to select the target HCW. It was planned to study HCWs during the rising curve, plateau, falling, and post fall steady state of incidence graph. However, 'no direct benefit to the tested individual' was raised and honoring the voice of dissent, it was decided to withhold target individual selection and make it an open invitation to all HCWs for volunteering. The sample gathered were 423, one hundred in excess of initial target. This reflects the enthusiasm of the HCW in volunteering for a study which can have only collective benefit.

The overall seropositivity in the current study was found to be 8.75%. This estimate is comparable to that of seroprevalence studies conducted among general population in the United States and Wuhan in China which have reported a seroprevalence of 6.9% and 3.8% respectively<sup>18,19</sup>. The prevalence of antibodies largely depends on the stage of the epidemic in the area at the time of the study. The findings of the present study contrast with the results of the population-based studies done in India. The nationwide study done in India in the early phase of the pandemic by the ICMR revealed a seroprevalence of 0.73% while the Sero-prevalence study across Delhi showed the prevalence of IgG antibodies to be 23.48%.<sup>20,21</sup> Studies done in similar settings among healthcare workers in Italy and India reported a seroprevalence of 14.4% and 11.94%. respectively<sup>22</sup>. The variability in prevalence in a large country with multiple local communities having varying health status, demographic profile and ecology is understandable. The containment strategies adopted by the local Governments had to follow the National guidelines, but the efficiency of it varied. This also would explain the variation.

The pattern of seropositivity across the different category of health workers observed in the present study showed a higher prevalence among nurses. This result agrees with a recent published report from united states.<sup>21</sup> These findings imply a higher occupational risk for SARS-CoV-2 infection among nurses. The Seropositivity was lowest among those working in nonclinical environments without patient contact. The history of upper respiratory symptoms in the past 3 months and a history of undergoing quarantine were

significantly associated with a higher probability of SARS-CoV-2 specific antibody positivity. This result was found to be consistent with a similar report from a hospital in North India.<sup>23,24</sup>

We found a significant linear association with covid 19 antibody positivity and severity of disease with the likelihood of being seropositive being highest for those with severe respiratory infections. During the initial phase of the pandemic, strategies that aimed to increase herd immunity by exposing young low-risk individuals to the virus were under consideration.<sup>25</sup> But early evidence suggested that acquired immunity may be short-lived in individuals with mild or asymptomatic infections<sup>26</sup>. Further studies confirmed that a stronger antibody response was associated with disease severity<sup>27</sup>.

Sero-positivity among the staff of our Institution showed a comparatively low figure. Even after a period of 10 months after the first case detection in the district and 6 months after first case detection in our own hospital, the development of immunity against Covid-19 remaining low is a matter of concern. Only when herd immunity develops or enough people are vaccinated, the pandemic of viral disease will get controlled and eradicated.

Right from the beginning of this pandemic and since the reporting of the first COVID 19 case of India from Thrissur our hospital has adopted strict infection control measures. Various measures were adopted by our institute to contain the spread. The classroom teaching for MBBS and Nursing were suspended and shift to online mode ensured, though with certain concerns<sup>28,29</sup>. A Multi-disciplinary Institutional Medical Board was constituted to take necessary actions regarding COVID positive patients and infection control among staff. The Hospital management under the guidance of the HICC provided necessary PPE for the staff as per the exposure risk & working environment and organised training through Online mode on Infection control measures<sup>30</sup>. COVID 19 testing for all In Patients & their bystanders. Staff surveillance team to assess exposure and quarantine of staff and their contacts. In-house testing facility for COVID PCR, Antigen & antibody testing were started. We assessed and facilitated willingness and emotional preparedness of staff in managing the cases well before the first admission<sup>31</sup>. The audit conducted after all preparations showed a fairly good level of practice. All these might have reduced the chance of exposure to virus during duty or at outside and hence the antibody development in them was low.

**Conclusions:** Keeping track of the pattern of development of immunity in the community is part of understanding the illness and forecasting the spread. For the tested HCW, it will boost up morale by ending uncertainty. For the hospital administration it will help in decision making about relative focusing of interventions on patients in general and HCWs. By knowing the immunity status of HCWs, the Institution will be able to contribute authentically to the development of intervention strategies<sup>32-34</sup> and guidelines from time to time, besides following the available guidelines. This is a responsibility of a leading academic institution with serving experts, whose expertise will remain dormant otherwise. Being an educational institution, it is obligatory to train all the elements of care delivery to the future generation of health care workers. It includes how to observe, confirm observations, identify the mechanisms behind it and develop



medRxiv preprint doi: <https://doi.org/10.1101/2021.01.27.21250502>; this version posted January 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

intervention strategies with rationale. Understanding the development of personal and herd immunity to a virus infection is hence inevitable. Getting experienced from a small but relevant sample was expected to facilitate larger community study envisaged in peripheral areas Jubilee served.

## References:

1. Brant-Zawadzki M, Fridman D, Robinson PA, Zahn M, Chau C, German R, et al. (2020) SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single center study. PLoS ONE 15(11): e0240006. <https://doi.org/10.1371/journal.pone.0240006>
2. Andrews MA, Areekal B, Rajesh KR, Krishnan J, Suryakala R, Krishnan B, Muraly CP, Santhosh PV. First confirmed case of COVID-19 infection in India: A case report. The Indian Journal of Medical Research. 2020 May;151(5):490
3. Menon JC, Rakesh PS, John D, et al. What was right about Kerala's response to the COVID-19 pandemic? BMJ Global Health 2020;5:e003212. doi:10.1136/bmjgh-2020-003212
4. Chathukulam, J., & Tharamangalam, J. (2021). The Kerala model in the time of COVID19: Rethinking state, society, and democracy. World development, 137, 105207. <https://doi.org/10.1016/j.worlddev.2020.105207>
5. Choolayil, A. C. and Putran, L. (2021) 'Covid-19, The local and the global: Lessons from Kerala', South Asia Research, 41(1), pp. 7–21. doi: 10.1177/0262728020966102).
6. Percivalle, E., Cambiè, G., Cassaniti, I., Nepita, E. V., Maserati, R., Ferrari, A., Di Martino, R., Isernia, P., Mojoli, F., Bruno, R., Tirani, M., Cereda, D., Nicora, C., Lombardo, M., & Baldanti, F. (2020). Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as a 06 April 2020. European communicable disease bulletin, 25(24), 2001031. <https://doi.org/10.2807/1560-7917.ES.2020.25.24.2001031>
7. Goenka MK, Afzalpurkar S, Goenka U, Das SS, Mukherjee M, Jajodia S, Shah BB, Patil VU, Rodge G, Khan U, Bandyopadhyay S. Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India. Available at SSRN 3689618. 2020 Oct 20.
8. Kumar N, Bhartiya S, Desai S, Mutha A, Beldar A, Singh T. Seroprevalence of Antibodies Against SARS-CoV-2 Among Health Care Workers in Mumbai, India. Asia Pacific Journal of Public Health. 2020 Nov 26:1010539520977307.
9. Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Thangaraj JW, Kumar MS, Shah N, Sabarinathan R, Turuk A, Anand PK. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian Journal of Medical Research. 2020 Jan 1;152(1):48.
10. Kumar A, Sathyapalan D, Ramachandran A, Subhash K, Biswas L, Beena KV. SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India. Clinical Microbiology and Infection. 2020 Sep 16
11. Ray A, Singh K, Chattopadhyay S, Mehdi F, Batra G, Gupta A, Agarwal A, Bhavesh M, Sahni S, Chaithra R, Agarwal S. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North India. medRxiv. 2020 Jan 1.
12. Malani A, Shah D, Kang G, Lobo GN, Shastri J, Mohanan M, Jain R, Agrawal S, Juneja S, Imad S, Kolthur-Seetharam U. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. The Lancet Global Health. 2020 Nov 13.
13. Ray A, Singh K, Chattopadhyay S, Mehdi F, Batra G, Gupta A, Agarwal A, Bhavesh M, Sahni S, Chaithra R, Agarwal S. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North India. medRxiv. 2020 Jan 1
14. <https://dhs.kerala.gov.in/wp-content/uploads/2020/10/Technical-Paper-COVID-19-ICMR-Sero-Surveillance-Study.docx.pdf>

15. Lin D, Liu L, Zhang M, et al. Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak. medRxiv 2020; 2020.03. 27.20045153. Preprint.
16. <https://news.abplive.com/news/india/kerala-cm-confirms-community-transmission-announces-more-restrictions-in-state-to-curb-coronavirus-1289424>
17. Luo Y, Trevathan E, Qian Z, Li Y, Li J, Xiao W, et al. Asymptomatic SARSCoV- 2 infection in household contacts of a healthcare provider, Wuhan, China. Emerg Infect Dis 2020;26:1930e3. <https://doi.org/10.3201/eid2608.201016>.
18. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, Fry AM, Cannon DL, Chiang CF, Gibbons A, Krapianaya I. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12 2020. JAMA internal medicine. 2020 Dec 1;180(12):1576-86.
19. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, Hou J, Huang X, Li D, Ma T, Peng J. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nature Medicine. 2020 Jun 5:1-3.
20. Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Thangaraj JW, Kumar MS, Shah N, Sabarinathan R, Turuk A, Anand PK. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian Journal of Medical Research. 2020 Jan 1;152(1):48.
21. 4.Sero-prevalence study conducted by National Center for Disease Control NCDC, MoHFW, in Delhi, June 2020. 2020. Available: <http://pib.gov.in/Pressreleaseshare.aspx?PRID=1640137>
22. Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, Colosio C, Felisati G, Davi M, Gerli AG, Centanni S. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. BMC Pulmonary Medicine. 2020 Dec;20(1):1-6
23. Barrett ES, Horton DB, Roy J, Gennaro ML, Brooks A, Tischfield J, Greenberg P, Andrews T, Jagpal S, Reilly N, Carson JL. Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers in New Jersey, at the onset of the US COVID-19 pandemic. BMC infectious diseases. 2020 Dec;20(1):1-0.]
24. Khan SM, Qurieshi MA, Haq I, Majid S, Bhat AA, Nabi S, Ganai NA, Zahoor N, Nisar A, Chowdri IN, Qazi TB. Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India—a cross-sectional study. PloS one. 2020 Nov 11;15(11):e0239303
25. Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19 protective immunity The Lancet. 2020 May 16;395(10236):1527-9
26. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature medicine. 2020 Aug;26(8):1200-
27. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, He X, Qian C, Sun Q, Hu Q, Liu H. Viral kinetics and antibody responses in patients with COVID-19. MedRxiv. 2020 Jan 1
28. Rafi AM, Varghese PR, Kuttichira P. The Pedagogical Shift During COVID 19 Pandemic: Online Medical Education, Barriers and Perceptions in Central Kerala. Journal of Medical Education and Curricular Development. January 2020. doi:10.1177/2382120520951795
29. Rafi AM, Varghese PR, Kuttichira P. Concerns and confidences expressed by teaching staff about the shift of medical education to online mode in South India during the COVID 19 pandemic. Journal of Ideas in Health. 2020 Dec 24;3(Special2):272-5.
30. Chithra Valsan,<sup>1</sup> Ronnie Thomas,<sup>2</sup> Joshi Paul Chirayath<sup>3</sup> , Varghese P R<sup>4</sup> , Praveenlal Kuttichira<sup>5</sup> . COVID-19 Essentials: Preparing Health Care Professionals before the Pandemic Spread in Kerala, India Vol. 12 No. (2021): Indian Journal of Public Health Research & Development )
31. Neethi Valsan, Ronnie Thomas, Praveenlal Kuttichira, Chithra Valsan, Anita James Willingness and psychological preparedness to attend to COVID-19 patients among healthcare workers in a tertiary care private hospital in Kerala-A mixed method study Kerala Journal of Psychiatry, 2020).
32. Rudberg AS, Havervall S, Månberg A, Falk AJ, Aguilera K, Ng H, Gabrielsson L, Salomonsson AC, Hanke L, Murrell B, McInerney G. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nature communications. 2020 Oct 8;11(1):1-8.

33. Khan MS, Haq I, Majid S, Bhat A, Sabir I, Kawoosa M, Lone A, Nabi S, Sumji I. SARS-CoV-2 seroprevalence in healthcare workers of dedicated COVID hospitals and non COVID hospitals of District Srinagar, Kashmir. medRxiv. 2020 Jan 1.
34. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A et al. Antibody tests for identification of current and past infection with SARS – CoV-2. Cochrane database of Systematic reviews 2020, Issue 6. Art No:CD013652.